Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Germany”
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Extensive Stage Small Cell Lung Cancer
United States, Austria, Canada, China, Czechia +7 more
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Active Not Recruiting
Sponsor: Swedish Orphan Biovitrum
VEXAS · VEXAS Syndrome
United States, Canada, France, Germany, Italy +3 more
Sponsor: Fondation Hôpital Saint-Joseph
Perimembranous Ventricular Septal Defect
Denmark, Egypt, France, Germany, Hong Kong +12 more
- Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)Active Not Recruiting
Sponsor: GlaxoSmithKline
Systemic Lupus Erythematosus
United States, Argentina, Germany, Japan, Mexico +2 more
- A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsRecruiting
Sponsor: AstraZeneca
Untreated Follicular Lymphoma
United States, Australia, Belgium, Brazil, Canada +18 more
Sponsor: Bayer
Chronic Kidney Disease · Proteinuria
United States, Argentina, Australia, Austria, Belgium +27 more
Sponsor: AstraZeneca
B-cell Acute Lymphoblastic Leukemia (B-ALL)
United States, Australia, Brazil, Canada, China +8 more
Sponsor: Bristol-Myers Squibb
Obstructive Hypertrophic Cardiomyopathy
United States, Austria, Czechia, France, Germany +4 more
Sponsor: Celgene
Multiple Sclerosis Spasticity
United States, Australia, Canada, Czechia, Germany +2 more
Sponsor: Boehringer Ingelheim
Small Cell Lung Cancer (SCLC) · Extensive-stage Small Cell Lung Cancer (ES-SCLC)
United States, Argentina, Australia, Austria, Belgium +37 more
Sponsor: Boston Scientific Corporation
Peripheral Vascular Diseases
United States, Australia, Austria, Canada, China +7 more
Sponsor: BeOne Medicines
Chronic Lymphocytic Leukemia
United States, Australia, Brazil, Canada, China +12 more
- Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsActive Not Recruiting
Sponsor: Pfizer
Hemophilia A
United States, Australia, Brazil, Canada, France +11 more
- PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717Active Not Recruiting
Sponsor: Ionis Pharmaceuticals, Inc.
Prion Disease
United States, Australia, Canada, France, Germany +4 more
- A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodNot Yet Recruiting
Sponsor: Boehringer Ingelheim
Healthy
Germany
- Open-Label Extension Study to Assess GLM101 in PMM2-CDG PatientsEnrolling By Invitation
Sponsor: Glycomine, Inc.
Pmm2-CDG · Phosphomannomutase 2 Deficiency
United States, Czechia, France, Germany, Italy +3 more
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
United States, Argentina, Australia, China, France +11 more
Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine
COPD (Chronic Obstructive Pulmonary Disease)
Germany
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1Enrolling By Invitation
Sponsor: Avidity Biosciences, Inc.
Myotonic Dystrophy Type 1 · DM1 · Myotonic Dystrophy · Myotonia
United States, Canada, Denmark, France, Germany +5 more
Sponsor: Technical University of Munich
Cardiovascular Diseases · Pediatric Cancer
Germany
Sponsor: Mission Therapeutics
Parkinson's Disease (PD) · Mild to Moderate Parkinson's Disease · Early Stage Parkinson's Disease
Australia, France, Germany, United Kingdom
Sponsor: Boehringer Ingelheim
Extrapulmonary Neuroendocrine Cancer (epNEC)
United States, Argentina, Australia, Austria, Belgium +24 more
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisActive Not Recruiting
Sponsor: Incyte Corporation
Atopic Dermatitis
United States, Belgium, Canada, France, Germany +5 more
- First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)Active Not Recruiting
Sponsor: CatalYm GmbH
Solid Tumor, Adult
Germany, Spain, Switzerland
Sponsor: Philipps University Marburg
Breast Cancer
Germany